Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations

Metabolism: Clinical and Experimental

Volumn 56, Issue 6, 2007, Pages 757-765

  Lima, John J ^a   Feng, Hua ^b   Duckworth, Laurie ^a   Wang, Jianwei ^a   Sylvester, James E ^a   Kissoon, Niranjan ^c   Garg, Hardesh ^d  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c BC CHILDREN S HOSPITAL   (Canada)

^d Medisolare Wellness and Cosmetic Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; INSULIN;

ADULT; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC DISORDER; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

ADULT; AFRICAN AMERICANS; BLOOD GLUCOSE; BODY MASS INDEX; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC;

EID: 34248384002     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.01.007     Document Type: Article

References (59)

1. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
2. Despres J.P., and Mareette A. Obesity and insulin resistance epidemiologic, metabolic, and molecular aspects. In: Reaven G., and Laws A. (Eds). Contemporary endocrinology: insulin resistance (1999), Humana Press Inc, Totowa 51-81
3. Haffner C.A., Kendall M.J., Maxwell S., et al. The lipolytic effect of beta 1- and beta 2-adrenoceptor activation in healthy human volunteers. Br J Clin Pharmacol 35 (1993) 35-39
4. Govindarajan G., Whaley-Connell A., Mugo M., et al. The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci 330 (2005) 311-318
5. Baillargeon J., and Rose D.P. Obesity, adipokines, and prostate cancer (review). Int J Oncol 28 (2006) 737-745
6. Gunter M.J., and Leitzmann M.F. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17 (2006) 145-156
7. Loos R.J., and Bouchard C. Obesity-is it a genetic disorder?. J Intern Med 254 (2003) 401-425
8. Loos R.J., and Rankinen T. Gene-diet interactions on body weight changes. J Am Diet Assoc 105 (2005) S29-S30
9. Coppack S.W., Jensen M.D., and Miles J.M. In vivo regulation of lipolysis in humans. J Lipid Res 35 (1994) 177-193
10. Large V., and Arner P. Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 24 (1998) 409-418
11. Barbe P., Millet L., Galitzky J., et al. In situ assessment of the role of the beta 1-, beta 2- and beta 3- adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol 117 (1996) 907-913
12. Stich V., de G.I., Crampes F., et al. Activation of antilipolytic alpha(2)-adrenergic receptors by epinephrine during exercise in human adipose tissue. Am J Physiol 277 (1999) R1076-R1083
13. Hellstrom L., Rossner S., Hagstrom-Toft E., et al. Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity-a metabolic predictor of weight loss in obese subjects. Int J Obes Relat Metab Disord 21 (1997) 314-320
14. Stich V., Pelikanova T., Wohl P., et al. Activation of alpha2-adrenergic receptors blunts epinephrine-induced lipolysis in subcutaneous adipose tissue during a hyperinsulinemic euglycemic clamp in men. Am J Physiol Endocrinol Metab 285 (2003) E599-E607
15. Arner P. Catecholamine-induced lipolysis in obesity. [In Process Citation]. Int J Obes Relat Metab Disord 23 Suppl 1 (1999) 10-13
16. Blaak E.E., vanBaak M.A., Kemerink G.J., et al. Beta-adrenergic stimulation of energy expenditure and forearm skeletal muscle metabolism in lean and obese men. Am J Physiol 267 (1994) E306-E315
17. Reynisdottir S., Ellerfeldt K., Wahrenberg H., et al. Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest 93 (1994) 2590-2599
18. Bougneres P., Stunff C.L., Pecqueur C., et al. In vivo resistance of lipolysis to epinephrine. A new feature of childhood onset obesity. J Clin Invest 99 (1997) 2568-2573
19. Horowitz J.F., Coppack S.W., Paramore D., et al. Effect of short-term fasting on lipid kinetics in lean and obese women. Am J Physiol 276 (1999) E278-E284
20. Rosmond R. Association studies of genetic polymorphisms in central obesity: a critical review. Int J Obes Relat Metab Disord 27 (2003) 1141-1151
21. Leineweber K., Buscher R., Bruck H., et al. B-adrenoceptor polymorphisms. Naunyn-Schmiedeberg's Arch Pharmacol 369 (2004) 1-22
22. Rankinen T., Zuberi A., Chagnon Y.C., et al. The human obesity gene map: the 2005 update. Obesity (Silver Spring) 14 (2006) 529-644
23. Durnin J.V., and Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32 (1974) 77-97
24. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
25. Johnson J.A., and Lima J.J. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 13 (2003) 525-534
26. Terra S.G., McGorray S.P., Wu R., et al. Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int J Obes (Lond) 29 (2005) 746-754
27. Wang J., Mougey E.B., David C.J., et al. Determination of human B2-adrenoceptor haplotypes by denaturation selective amplification and subtractive genotyping. Am J Pharmacogenomics 1 (2001) 1175-2203
28. D'amato M., Vitiani L.R., Petrelli G., et al. Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population study. Am J Respir Crit Care Med 158 (1998) 1968-1973
29. Myers R. Classical and modern regression with applications. 2nd ed. (1990), Duxbury Press, Belmont, CA
30. Balding D., and Bishop M. Handbook of statistical genetis (2001), Wiley, Hoboken, NJ
31. Agresti A. Categoracal data analysis. 2nd ed (2002), Wiley, Hoboken, NJ
32. Conover W. Practical nonparametric statistics. 3rd ed. (1999), John Wiley & Sons Inc, Hoboken, NJ
33. Rao P. Statistical research methods in life sciences (1992), Brooks Cole, Pacific Grove, CA
34. Utts J., and Heckard R. Mind on statistics. 2nd ed. (2004), Duxbury Press, Belmont, CA
35. Tafel J., Branscheid I., Skwarna B., et al. Variants in the human beta 1-, beta 2-, and beta 3-adrenergic receptor genes are not associated with morbid obesity in children and adolescents. Diabetes Obes Metab 6 (2004) 452-455
36. Dionne I.J., Garant M.J., Nolan A.A., et al. Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. Int J Obes Relat Metab Disord 26 (2002) 633-639
37. Mason D.A., Moore J.D., Green S.A., et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274 (1999) 12670-12674
38. Sandilands A.J., O'Shaughnessy K.M., and Brown M.J. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial myocardium. Br J Pharmacol 138 (2003) 386-392
39. Esler M., Rumantir M., Wiesner G., et al. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14 (2001) 304S-309S
40. Straznicky N.E., Lambert E.A., Lambert G.W., et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 90 (2005) 5998-6005
41. Ryden M., Hoffstedt J., Eriksson P., et al. The Arg 389 Gly beta1-adrenergic receptor gene polymorphism and human fat cell lipolysis. Int J Obes Relat Metab Disord 25 (2001) 1599-1603
42. Linne Y., Dahlman I., and Hoffstedt J. beta1-Adrenoceptor gene polymorphism predicts long-term changes in body weight. Int J Obes (Lond) 29 (2005) 458-462
43. Levin M.C., Marullo S., Muntaner O., et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277 (2002) 30429-30435
44. Rathz D.A., Brown K.M., Kramer L.A., et al. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39 (2002) 155-160
45. Drysdale C.M., McGraw D.W., Stack C.B., et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad U S A Sci 97 (2000) 10483-10488
46. Large V., Hellstrom L., Reynisdottir S., et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 100 (1997) 3005-3013
47. Belfer I., Buzas B., Hipp H., et al. Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene. J Hum Genet 50 (2005) 12-20
48. Li J.L., Canham R.M., Vongpatanasin W., et al. Do allelic variants in {alpha}2A and {alpha}2C adrenergic receptors predispose to hypertension in blacks?. Hypertension 47 (2006) 1140-1146
49. Oppert J.M., Tourville J., Chagnon M., et al. DNA polymorphisms in the alpha 2- and beta 2-adrenoceptor genes and regional fat distribution in humans: association and linkage studies. Obes Res 3 (1995) 249-255
50. Ukkola O., Perusse L., Chagnon Y.C., et al. Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec Family Study. Int J Obes Relat Metab Disord 25 (2001) 1332-1339
51. Wolfarth B., Rivera M.A., Oppert J.M., et al. A polymorphism in the alpha2a-adrenoceptor gene and endurance athlete status. Med Sci Sports Exerc 32 (2000) 1709-1712
52. Rosmond R., Bouchard C., and Bjorntorp P. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. J Intern Med 251 (2002) 252-257
53. Ukkola O., Rankinen T., Weisnagel S.J., et al. Interactions among the alpha2-, beta2-, and beta3-adrenergic receptor genes and obesity-related phenotypes in the Quebec Family Study. Metabolism 49 (2000) 1063-1070
54. Zimmet P., Magliano D., Matsuzawa Y., et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12 (2005) 295-300
55. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
56. Dallongeville J., Helbecque N., Cottel D., et al. The Gly16->Arg16 and Gln27->Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocrinol Metab 88 (2003) 4862-4866
57. Fumeron F., Aubert R., Siddiq A., et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 53 (2004) 1150-1157
58. Hirschhorn J.N., and Daly M.J. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6 (2005) 95-108
59. Pritchard J.K., and Rosenberg N.A. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65 (1999) 220-228